BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wilde L, Ramanathan S, Kasner M. B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia. World J Clin Oncol 2020; 11(8): 528-540 [PMID: 32879842 DOI: 10.5306/wjco.v11.i8.528]
URL: https://www.wjgnet.com/2218-4333/full/v11/i8/528.htm
Number Citing Articles
Juan Tong, Na Zhao, Xing Hu, Wen Yao, Yaxin Cheng, Li Zhou, Huilan Liu, Liangquan Geng, Zimin Sun, Changcheng Zheng. Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World SettingCancer Management and Research 2021; : 5613 doi: 10.2147/CMAR.S316561
Romeo G. Mihăilă. Venetoclax in Acute Myeloid LeukemiaRecent Patents on Anti-Cancer Drug Discovery 2023; 18(1): 11 doi: 10.2174/1574892817666220429105338
Abhishek Maiti, Bing Z. Carter, Michael Andreeff, Marina Y. Konopleva. SOHO State of the Art Updates and Next Questions | Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic PathwayClinical Lymphoma Myeloma and Leukemia 2022; 22(9): 652 doi: 10.1016/j.clml.2022.04.001
Erin M Kropp, Qing Li. Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemiaExperimental Hematology 2022; 111: 13 doi: 10.1016/j.exphem.2022.04.001
Linzhang Li, Chengwu Han, Xueying Yu, Jun Shen, Yongtong Cao, Enas Abdulhay. Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-AnalysisJournal of Healthcare Engineering 2022; 2022: 1 doi: 10.1155/2022/2842066